Survival of patients with urinary bladder cancer in Jordan, 2005–2014

Background: Urinary bladder cancer is the fourth most common cancer in Jordan. No research on survival from bladder cancer at the national level has been conducted before. Aims: This study aimed to estimate the probability of survival in patients with bladder cancer in Jordan and identify factors associated with survival. Methods: Data were obtained from the database of the Jordan cancer registry. All cases of urinary bladder cancer in Jordanians registered during 2005–2014 were included in the study (n = 2139). Data collected for each case included: age, sex, date of diagnosis, and stage and grade at diagnosis. Actuarial life table survival analysis was used to determine the overall survival probabilities. Cox proportional hazard regression was used to identify independent factors associated with survival. Results: The overall 1-, 3-, 5- and 10-year survival probabilities for urinary bladder cancer were 85%, 73%, 69% and 59%, respectively (standard error = 0.01 for each). No significant difference in survival probabilities was found between males and females (P = 0.642). The overall survival probabilities decreased significantly as age at diagnosis increased (P < 0.005). Better survival was observed in patients with early stage and well differentiated tumours at diagnosis. Conclusions: The survival of patients with bladder cancer in Jordan is comparable to that reported from developed countries. A high percentage of data was missing and the reporting of some variables was inconsistent. To improve the quality of cancer data, regular training is needed for hospital focal points on recording complete data.

Download Full-text

A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer

Journal of Cancer ◽

10.7150/jca.30307 ◽

2019 ◽

Vol 10 (23) ◽

pp. 5744-5753 ◽

Cited By ~ 3

Author(s):

Siteng Chen ◽

Ning Zhang ◽

Jialiang Shao ◽

Tao Wang ◽

Xiang Wang

Keyword(s):

Overall Survival ◽

Bladder Cancer ◽

Urinary Bladder ◽

Urinary Bladder Cancer ◽

Gene Signature ◽

Novel Gene

Download Full-text

Bayesian nonparametric areal wombling for small-scale maps with an application to urinary bladder cancer data from Connecticut

Statistics in Medicine ◽

10.1002/sim.7408 ◽

2017 ◽

Vol 36 (25) ◽

pp. 4007-4027

Author(s):

Rajarshi Guhaniyogi

Keyword(s):

Bladder Cancer ◽

Urinary Bladder ◽

Urinary Bladder Cancer ◽

Small Scale ◽

Bayesian Nonparametric ◽

Cancer Data

Download Full-text

Retrospective analysis of clinico-epidemiological factors and clinical outcome in patients with urinary bladder carcinoma

QJM ◽

10.1093/qjmed/hcaa057.002 ◽

2020 ◽

Vol 113 (Supplement_1) ◽

Author(s):

E M Elsheikh ◽

D R D Ibrahim ◽

O M Abdelrahman ◽

H M Ali

Keyword(s):

Overall Survival ◽

Bladder Cancer ◽

Adjuvant Chemotherapy ◽

Urinary Bladder ◽

Cell Carcinoma ◽

Performance Status ◽

Transitional Cell ◽

Urinary Bladder Cancer ◽

Tumor Stage ◽

Treatment Modalities

Abstract Background Bladder cancer ranks ninth in worldwide cancer incidence and it is the second most common malignancy among Egyptian males. Urothelial carcinoma (UC) of the bladder (previously known as transitional cell carcinoma; TCC)is the predominant histologic type, the two most well-established risk factors for bladder are cigarette smoking and occupational exposure to urothelial carcinogens. Aim of the Work To analyze retrospectively the clinico-pathological features of urinary bladder cancer patients treated in Clinical Oncology Department of Ain Shams University Hospitals in Egypt. Patients and Methods All 127 eligible patients fulfilling the inclusion criteria and the medical sheets were reviewed including history, clinical examination, routine laboratory tests, radiological investigations, and follow up. Several prognostic factors were analyzed in our study including age, sex, performance status, tumor size, site, grade, extent of surgery and type of treatment as regard chemotherapy and radiotherapy. Results Among the included 127 patients, populatge ranged from 30 to 75 years. Males represented 81.9 % of the patients with a male to female ratio of 4:1. Eastern Cooperative Oncology Group (ECOG) performance status of patients at presentation was ECOG 1 in 82 patients (64.6%). The majority of the studied population presented with haematuria. The most common histological subtype in biopsied specimens was transitional cell carcinoma in 75.5% of the patients.78 patients presented with non-metastatic and 47 patients with metastatic urinary bladder cancer. The median progression-free survival (PFS) was found to be 17 months and similarly the median overall survival (OS) was 17 months. In our study we found a significant correlation between age, performance status (PS), smoking, tumor stage and the treatment modalities such as surgery and adjuvant chemotherapy with the overall survival. Conclusion The epidemiology of bladder cancer was dramatically shifted in Egypt with a lower incidence of squamous cell carcinoma (SCC), a greater incidence of TCC and older age at diagnosis. Age, PS, smoking, tumor stage and the treatment modalities such as surgery and adjuvant chemotherapy were proved to affect the overall survival.

Download Full-text

Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival

Scandinavian Journal of Urology ◽

10.1080/21681805.2020.1716067 ◽

2020 ◽

Vol 54 (1) ◽

pp. 46-51 ◽

Cited By ~ 1

Author(s):

Robert Rosenblatt ◽

Gabriella Lorentzi ◽

Maryam Bahar ◽

Danna Asad ◽

Ramona Forsman ◽

...

Keyword(s):

Overall Survival ◽

Bladder Cancer ◽

Neoadjuvant Chemotherapy ◽

Urinary Bladder ◽

Negative Impact ◽

Urinary Bladder Cancer ◽

Blood Transfusions ◽

Muscle Invasive

Download Full-text

The value of clinical prognostic factors for survival in patients with invasive urinary bladder cancer

Medicina ◽

10.3390/medicina46050043 ◽

2010 ◽

Vol 46 (5) ◽

pp. 305 ◽

Cited By ~ 5

Author(s):

Jolita Asadauskienė ◽

Eduardas Aleknavičius ◽

Teresė Želvienė ◽

Feliksas Jankevičius

Keyword(s):

Overall Survival ◽

Bladder Cancer ◽

Prognostic Factors ◽

Urinary Bladder ◽

Radical Cystectomy ◽

Significant Influence ◽

Univariate Analysis ◽

Urinary Bladder Cancer ◽

Group Completion ◽

Cystectomy Group

The aim of the study was to evaluate the value of clinical prognostic factors for survival of patients with invasive urinary bladder cancer treated with radical cystectomy, chemotherapy, and radiotherapy. Material and methods. A total of 115 patients with invasive urinary bladder cancer were analyzed. Twenty-three patients with invasive urinary bladder cancer (pT2–T4) were treated according to the protocol of a prospective clinical study. In all the cases, transurethral resection was followed by radiation and chemotherapy. A total dose of 54–60 Gy of radiotherapy was delivered by daily fractions of 1.8–2.0 Gy each. Simultaneous chemotherapy was started on the same day as radiotherapy; gemcitabine at a dose of 175–300 mg/m2 was delivered once a week intravenously for 6 weeks. Individual patient data was analyzed in a retrospective part of the study. Radical cystectomy was performed to 46 patients with invasive urinary bladder cancer, and radiotherapy was delivered to 46 patients. Inclusion criteria for patients into a prospective or retrospective trial were equal. We evaluated a prognostic value of various clinical factors for patients treated with radical cystectomy, chemoradiation with gemcitabine, and radiation alone. Results. The 3-year overall survival in the cystectomy group was 51.1%, in the chemoradiation group 38.0%, and in the radiotherapy group 26.9% (P=0.001). In univariate analysis in the chemoradiation group, completion of treatment according to the protocol showed a significant influence on overall survival (P=0.03). In the radiation group, completion of treatment according to the protocol showed a significant influence on overall survival too (P=0.01). In the radical cystectomy group, an important factor was a complete or incomplete TUR (P=0.02). Multivariate analysis showed a significance of hydronephrosis (P=0.03) and T stage (P=0.04) in the radiation therapy group. Comorbidity was found to be an independent prognostic factors in the chemoradiation group (P=0.02). Conclusions. The best 3-year overall survival was in the radical cystectomy group. Chemoradiation with gemcitabine could be offered as an alternative to patients refusing cystectomy. Better overall survival in the chemoradiation group was for patients without comorbidities and when treatment protocol was completed.

Download Full-text

Treatment and prognosis of patients with urinary bladder cancer with other primary cancers: a nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe)

BJU International ◽

10.1111/bju.15198 ◽

2020 ◽

Vol 126 (5) ◽

pp. 625-632

Author(s):

Firas Aljabery ◽

Fredrik Liedberg ◽

Christel Häggström ◽

Viveka Ströck ◽

Abolfazl Hosseini ◽

...

Keyword(s):

Bladder Cancer ◽

Urinary Bladder ◽

Data Base ◽

Urinary Bladder Cancer ◽

Population Based ◽

Population Based Study ◽

Cancer Data

Download Full-text

Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)

BMJ Open ◽

10.1136/bmjopen-2017-016606 ◽

2017 ◽

Vol 7 (9) ◽

pp. e016606 ◽

Cited By ~ 17

Author(s):

Christel Häggström ◽

Fredrik Liedberg ◽

Oskar Hagberg ◽

Firas Aljabery ◽

Viveka Ströck ◽

...

Keyword(s):

Bladder Cancer ◽

Urinary Bladder ◽

Data Base ◽

Cancer Survival ◽

Urinary Bladder Cancer ◽

Remote Access ◽

National Register ◽

Cancer Data ◽

Muscle Invasive

PurposeTo monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).ParticipantsThe SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in the SNRUBC from 1997 to 2014, and additional covariates and follow-up data from linked national register sources on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.Findings to dateStudies based on data in the SNRUBC have shown inequalities in survival and treatment indication by gender, regions and hospital volume. The BladderBaSe includes 38 658 participants registered in SNRUBC with bladder cancer diagnosed from 1 January 1997 to 31 December 2014. The BladderBaSe initiators are currently in collaboration with researchers from the SNRUBC investigating different aspects of bladder cancer survival.Future plansThe SNRUBC and the BladderBaSe project are open for collaborations with national and international research teams. Collaborators can submit proposals for studies and study files can be uploaded to servers for remote access and analysis. For more information, please contact the corresponding author.

Download Full-text